Reuters logo
BRIEF-FDA grants priority status to Gilead's HIV treatments
August 10, 2017 / 8:25 PM / 4 months ago

BRIEF-FDA grants priority status to Gilead's HIV treatments

Aug 10 (Reuters) - Gilead Sciences Inc-

* Gilead announces U.S. fda priority review designation for fixed-dose combination of bictegravir, emtricitabine and tenofovir alafenamide for treatment of HIV

* Gilead Sciences Inc - ‍FDA has set a target action date under prescription drug user fee act (pdufa) of February 12, 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below